Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain

on behalf of The PSYCHOCOKE investigators

doi:10.3389/fpsyt.2021.704276

Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain

on behalf of The PSYCHOCOKE investigators

Economics

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Introduction: Cocaine users often present with repetitive events of cocaine-associated chest pain (CACP), clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for CACP. Method: Cocaine users (n = 316) were recruited for a multicenter cross-sectional study. Lifetime CACP history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms (SNPs) of NOS3, ROCK2, EDN1, GUCY1A3, and ALDH2 genes, suggested by the literature on coronary spasms, were selected. The associations with CACP history were tested using the chi-square test, Student's t-test and logistic regression. Results: Among the 316 subjects [78.5% men, mean age 37.5 years, (standard-deviation ±8.7)], 190 (60.1%) were daily cocaine users and 103 (32.6%) reported a lifetime CACP history. Among those with a lifetime CACP history, the median was 10 events per individual. In multivariate analysis, lifetime CACP history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95% confidence intervals (1.29–9.33)], rapid route of cocaine use [OR 2.33 (1.20–4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25–6.32) and non-daily amphetamine use: OR 2.14 (1.15–4.04) vs. never used]. Patients with lifetime opioid maintenance treatment (OMT) reported significantly less lifetime CACP history [OR 0.35 (0.16–0.76)]. None of the selected SNPs was associated with CACP history after multiple testing corrections. Conclusions: Clinical variables describing the intensity of stimulant use were positively associated with lifetime CACP history, while OMT was negatively associated with it. Specific harm reduction strategies can target these risk factors.

Original language	English
Article number	704276
Pages (from-to)	1-10
Number of pages	10
Journal	Frontiers in Psychiatry
Volume	12
Issue number	July
Early online date	21 Jul 2021
DOIs	https://doi.org/10.3389/fpsyt.2021.704276
Publication status	Published - Jul 2021

Bibliographical note

Funding

The authors thank the professional English proofreading services of Taylor and Francis Editing Services. Funding. This study was funded by the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National 2010 AOM10165) to FV. The Délégation de la Recherche Clinique et du Développement (DRCD) from the Assistance Publique-Hôpitaux de Paris (APHP) endorsed the study. Furthermore, FV received in the past 5 years grants from the ERANET-Neuron Joint Transnational Call for European Research Projects on Synaptic dysfunction 2017 (ANR-17-NEU3-0002-05), from the Labex BioPsy (Twice in 2016), a French state fund managed by the ANR within the Investissements d'Avenir program under reference ANR-11-IDEX-0004-02, from the Fondation pour la Recherche en Alcoologie (Fondation de France) 2016 and 2018, from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National 2018 PHRC-N-180777), and from the FHU NOR-SUD (INSERM/APHP/Université de Paris) internal call (2020). VC-D received a grant from the FHU NOR-SUD (INSERM/APHP/Université de Paris) internal call (2020). FB was the Principal Investigator on the R-LiNK (Response to Lithium Network) project. This project has received funding from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No. 754907). AM was supported by the Netherlands Organization for Research (NWO) Vidi grant 0.16.Vidi.185.044. This study was funded by the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National 2010 AOM10165) to FV. The Délégation de la Recherche Clinique et du Développement (DRCD) from the Assistance Publique-Hôpitaux de Paris (APHP) endorsed the study. Furthermore, FV received in the past 5 years grants from the ERANET-Neuron Joint Transnational Call for European Research Projects on Synaptic dysfunction 2017 (ANR-17-NEU3-0002-05), from the Labex BioPsy (Twice in 2016), a French state fund managed by the ANR within the Investissements d’Avenir program under reference ANR-11-IDEX-0004-02, from the Fondation pour la Recherche en Alcoologie (Fondation de France) 2016 and 2018, from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC National 2018 PHRC-N-180777), and from the FHU NOR-SUD (INSERM/APHP/Université de Paris) internal call (2020). VC-D received a grant from the FHU NOR-SUD (INSERM/APHP/Université de Paris) internal call (2020). FB was the Principal Investigator on the R-LiNK (Response to Lithium Network) project. This project has received funding from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: Grant No. 754907). AM was supported by the Netherlands Organization for Research (NWO) Vidi grant 0.16.Vidi.185.044.

Funders	Funder number
Délégation de la Recherche Clinique et du Développement
DRCD
FHU
Fondation pour la Recherche en Alcoologie
Assistance Publique - Hôpitaux de Paris
Horizon 2020
Ministère des Affaires Sociales et de la Santé	2010 AOM10165, ANR-17-NEU3-0002-05
Fondation de France	PHRC-N-180777
Horizon 2020 Framework Programme	754907
Nederlandse Organisatie voor Wetenschappelijk Onderzoek	0.16
Labex BioPsy	ANR-11-IDEX-0004-02
???publication-publication-funding-organisation-not-added???	ANR-17-NEU3-0002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3389/fpsyt.2021.704276Licence: CC BY

Persistent URL (handle)

Persistent link

Cite this

@article{dbbbe22fbf7648768a6a0c05aa94eb1d,

title = "Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain",

abstract = "Introduction: Cocaine users often present with repetitive events of cocaine-associated chest pain (CACP), clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for CACP. Method: Cocaine users (n = 316) were recruited for a multicenter cross-sectional study. Lifetime CACP history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms (SNPs) of NOS3, ROCK2, EDN1, GUCY1A3, and ALDH2 genes, suggested by the literature on coronary spasms, were selected. The associations with CACP history were tested using the chi-square test, Student's t-test and logistic regression. Results: Among the 316 subjects [78.5\% men, mean age 37.5 years, (standard-deviation ±8.7)], 190 (60.1\%) were daily cocaine users and 103 (32.6\%) reported a lifetime CACP history. Among those with a lifetime CACP history, the median was 10 events per individual. In multivariate analysis, lifetime CACP history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95\% confidence intervals (1.29–9.33)], rapid route of cocaine use [OR 2.33 (1.20–4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25–6.32) and non-daily amphetamine use: OR 2.14 (1.15–4.04) vs. never used]. Patients with lifetime opioid maintenance treatment (OMT) reported significantly less lifetime CACP history [OR 0.35 (0.16–0.76)]. None of the selected SNPs was associated with CACP history after multiple testing corrections. Conclusions: Clinical variables describing the intensity of stimulant use were positively associated with lifetime CACP history, while OMT was negatively associated with it. Specific harm reduction strategies can target these risk factors.",

author = "V. Clergue-Duval and L. Nicolas-Sacy and E. Karsinti and E.-H. Zerdazi and J.-L. Laplanche and G. Brousse and A.T. Marees and E.M. Derks and P. Henry and F. Bellivier and F. Vorspan and V. Bloch and \{on behalf of The PSYCHOCOKE investigators\}",

note = "{\textcopyright} Copyright {\textcopyright} 2021 Clergue-Duval, Nicolas-Sacy, Karsinti, Zerdazi, Laplanche, Brousse, Marees, Derks, Henry, Bellivier, Vorspan and Bloch.",

year = "2021",

month = jul,

doi = "10.3389/fpsyt.2021.704276",

language = "English",

volume = "12",

pages = "1--10",

journal = "Frontiers in Psychiatry",

issn = "1664-0640",

publisher = "Frontiers Media S.A.",

number = "July",

}

TY - JOUR

T1 - Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain

AU - Clergue-Duval, V.

AU - Nicolas-Sacy, L.

AU - Karsinti, E.

AU - Zerdazi, E.-H.

AU - Laplanche, J.-L.

AU - Brousse, G.

AU - Marees, A.T.

AU - Derks, E.M.

AU - Henry, P.

AU - Bellivier, F.

AU - Vorspan, F.

AU - Bloch, V.

AU - on behalf of The PSYCHOCOKE investigators

PY - 2021/7

Y1 - 2021/7

N2 - Introduction: Cocaine users often present with repetitive events of cocaine-associated chest pain (CACP), clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for CACP. Method: Cocaine users (n = 316) were recruited for a multicenter cross-sectional study. Lifetime CACP history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms (SNPs) of NOS3, ROCK2, EDN1, GUCY1A3, and ALDH2 genes, suggested by the literature on coronary spasms, were selected. The associations with CACP history were tested using the chi-square test, Student's t-test and logistic regression. Results: Among the 316 subjects [78.5% men, mean age 37.5 years, (standard-deviation ±8.7)], 190 (60.1%) were daily cocaine users and 103 (32.6%) reported a lifetime CACP history. Among those with a lifetime CACP history, the median was 10 events per individual. In multivariate analysis, lifetime CACP history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95% confidence intervals (1.29–9.33)], rapid route of cocaine use [OR 2.33 (1.20–4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25–6.32) and non-daily amphetamine use: OR 2.14 (1.15–4.04) vs. never used]. Patients with lifetime opioid maintenance treatment (OMT) reported significantly less lifetime CACP history [OR 0.35 (0.16–0.76)]. None of the selected SNPs was associated with CACP history after multiple testing corrections. Conclusions: Clinical variables describing the intensity of stimulant use were positively associated with lifetime CACP history, while OMT was negatively associated with it. Specific harm reduction strategies can target these risk factors.

AB - Introduction: Cocaine users often present with repetitive events of cocaine-associated chest pain (CACP), clinically resembling acute coronary syndromes. The aim of the study is to describe the specific risk factors for CACP. Method: Cocaine users (n = 316) were recruited for a multicenter cross-sectional study. Lifetime CACP history, sociodemographic factors, and lifetime use of cocaine and other substances were assessed. Thirty single nucleotide polymorphisms (SNPs) of NOS3, ROCK2, EDN1, GUCY1A3, and ALDH2 genes, suggested by the literature on coronary spasms, were selected. The associations with CACP history were tested using the chi-square test, Student's t-test and logistic regression. Results: Among the 316 subjects [78.5% men, mean age 37.5 years, (standard-deviation ±8.7)], 190 (60.1%) were daily cocaine users and 103 (32.6%) reported a lifetime CACP history. Among those with a lifetime CACP history, the median was 10 events per individual. In multivariate analysis, lifetime CACP history was associated with daily cocaine use [odds-ratio (OR) 3.24; 95% confidence intervals (1.29–9.33)], rapid route of cocaine use [OR 2.33 (1.20–4.64) vs. intranasal use], and lifetime amphetamine use [daily amphetamine use: OR 2.80 (1.25–6.32) and non-daily amphetamine use: OR 2.14 (1.15–4.04) vs. never used]. Patients with lifetime opioid maintenance treatment (OMT) reported significantly less lifetime CACP history [OR 0.35 (0.16–0.76)]. None of the selected SNPs was associated with CACP history after multiple testing corrections. Conclusions: Clinical variables describing the intensity of stimulant use were positively associated with lifetime CACP history, while OMT was negatively associated with it. Specific harm reduction strategies can target these risk factors.

UR - https://www.scopus.com/pages/publications/85111944785

UR - https://www.scopus.com/pages/publications/85111944785#tab=citedBy

U2 - 10.3389/fpsyt.2021.704276

DO - 10.3389/fpsyt.2021.704276

M3 - Article

SN - 1664-0640

VL - 12

SP - 1

EP - 10

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

IS - July

M1 - 704276

ER -

Risk and Protective Factors of Lifetime Cocaine-Associated Chest Pain

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this